Ultra Sound Guided Injection of Platelet Rich Plasma Versus Steroid for Sacroiliac Joint Pain
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sacroiliitis
- Sponsor
- Mansoura University
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- visual analog score
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
Comparison between the effect of steroids and platelet-rich plasma on low back pain after ultrasound-guided sacroiliac injection to determine any is more effective and of long duration
Detailed Description
A prospective randomized controlled study was conducted at the department of anesthesiology Mansoura University Hospital during the period from December 2017 to January 2019 on fifty ASA I-III adult patients, of both sex after approval of IRB (Institutional Review Board) ID number MS17.10.03 \& IRB date 12-11-2017. The patients were randomly allocated into two groups each of 25 patients according to computer-generated random number codes that were placed in sealed envelopes, double blinded, with parallel-group comparison. Steroid Group (S) (n. 25):- Patients were injected by 4 ml of sterile water containing the methylprednisolone Acetate (Depo-Medrol) per-kg calculated dose (0.5mg/kg up to a lean muscle body weight of 80kg in the painful sacroiliac joint). Platelet rich plasma Group (P) (n. 25):-Patients received fixed volume of 4 ml platelet-rich plasma in the inflamed painful sacroiliac joint.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients of either sex.
- •ASA I\&III.
- •Age between 18 - 70 years.
- •Chronic lower back pain of sacroiliac origin.
- •Anatomy of the joint can identified by the ultrasonography. Exclusion criteria
- •Patients with contraindications to sacroiliac injection.
- •Patients known to be allergic to platelet rich plasma or local anesthetics.
- •History of immune suppression or immune compromised diseases
- •Patient below age of 18 as the joint will undergo normal physiological changes.
- •Patient over 70 years.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
visual analog score
Time Frame: Basal and after 6 months
To evaluate the changes in visual analogue score over a 6-month follow-up period after intra-articular injection and compare these changes among the studied groups.